Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States

Lynn M. Malec, MD, Char M Witmer, MDMSCE, Julie Jaffray, MD, Peter A. Kouides, MD, Kristina M. Haley, DO, Robert F. Sidonio, Jr., MD, Dunlei Cheng, PhD, Thomas C. Abshire, MD, Gilbert C. White, MD, Margaret V. Ragni, MD MPH

Blood (2018) 132 (Supplement 1): 1195.

https://doi.org/10.1182/blood-2018-99-113956

Published: 2018

Journal Articles

Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program

Veronica H Flood, MD, Pamela A Christopherson, Joan Cox Gill, MD, Kenneth Dale Friedman, MD, Sandra L Haberichter, PhD, Jorge Di Paola, MD, Paula D. James, MD, Janna M. Journeycake, MD, Steven R. Lentz, MD PhD, Cindy A. Leissinger, MD, Margaret V. Ragni, MD MPH, Madhvi Rajpurkar, MD, Jonathan C. Roberts, MD, Amy Shapiro, Robert F. Sidonio, Robert R Montgomery, MD, Thomas C. Abshire, MD

Blood (2018) 132 (Supplement 1): 979.

https://doi.org/10.1182/blood-2018-99-110650

Published: 2018

Journal Articles

Contribution of Select ISTH-BAT Subscores to the Total Score in Type 1 VWD

Jessica Garcia, MD, Pamela A Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Robert R. Montgomery, MD, Paula D. James, MD, Pippa Simpson, PhD, Liyun Zhang, MS, Thomas C. Abshire, MD, Zimmerman Program Investigators

Blood (2017) 130 (Supplement 1): 1075.

https://doi.org/10.1182/blood.V130.Suppl_1.1075.1075

Published: 2017

Journal Articles

Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a

Beth Boulden Warren, MD MS, Linda Jacobsen, BS, Elizabeth Villalobos-Menuey, BS, Thomas C. Abshire, MD, Amy D Shapiro, MD, Michael Recht, MD PhD, Deborah Brown, MD, Cindy A. Leissinger, MD, Christine L. Kempton, MD MSc, Heidi Lane, PT, DPT, PCS, Diane J. Nugent, MD, Marilyn J. Manco-Johnson, MD

Blood (2015) 126 (23): 2289.

https://doi.org/10.1182/blood.V126.23.2289.2289

Published: 2015

Journal Articles

Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial

Neil A Goldenberg, MD PhD, Thomas C. Abshire, MD, Jonathan L Halperin, MD, William R. Hiatt, Craig M. Kessler, MD, John M Kittelson, PhD, Marilyn J. Manco-Johnson, MD, Alex Spyropoulos, MD, Phillipe Gabriel Steg, MD, Alexander G.G. Turpie, MD, Sam Schulman, MD PhD

Blood (2014) 124 (21): 4271.

https://doi.org/10.1182/blood.V124.21.4271.4271

Published: 2014

Journal Articles

Impact of Age and Gender on Bleeding Score in Type 1 VWD Using the ISTH-BAT

Pamela A Christopherson, Veronica H Flood, MD, Kenneth D. Friedman, MD, Joan Cox Gill, MD, Sandra L Haberichter, PhD, Robert R Montgomery, MD, Thomas C. Abshire, MD, the Zimmerman Program Investigators

Blood (2014) 124 (21): 1510.

https://doi.org/10.1182/blood.V124.21.1510.1510

Published: 2014

Journal Articles

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Erik Berntorp, MD, PhD, Thomas C. Abshire, MD, Augusto B. Federici, MD

Blood (2010) 116 (21): 236.

https://doi.org/10.1182/blood.V116.21.236.236

Published: 2010

Journal Articles

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

Christine L Kempton, MD, MSc, J. Michael Soucie, Ph.D, Connie H. Miller, PhD, Craig Hooper, PhD, Miguel A. Escobar, MD, Mark T. Reding, MD, Alice J. Cohen, MD, Nigel S. Key, MBChB, Arthur R. Thompson, M.D., Ph.D., Marilyn J. Manco-Johnson, Thomas C. Abshire, MD

Blood (2009) 114 (22): 3184.

https://doi.org/10.1182/blood.V114.22.3184.3184

Published: 2009

Journal Articles

The Kids-DOTT Trial: Novel Aspects of the ‘Parallel Cohort RCT‘ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.

Neil A. Goldenberg, MD, PhD, Mark Tripputi, PhD, MS, Mark A. Crowther, MD, Thomas C. Abshire, MD, Donna M. DiMichele, MD, Marilyn J. Manco-Johnson, William R Hiatt, MD

Blood (2009) 114 (22): 4169.

https://doi.org/10.1182/blood.V114.22.4169.4169

Published: 2009

Journal Articles

Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor

Connie H. Miller, PhD, Craig Hooper, PhD, Thomas C. Abshire, MD, Paula L. Bockenstedt, MD, Doreen B. Brettler, MD, Jorge Di Paola, MD, Gita Massey, MD, Anne T. Neff, MD, Amy D. Shapiro, MD, Michael Tarantino, MD, Brian M. Wicklund, MD, MPH, Marilyn J. Manco-Johnson, MD, Amy L. Dunn, MD, Christine Knoll, MD, Melissa Creary, MPH, Jane Benson, Dorothy Ellingsen, Jennifer Driggers, J. Michael Soucie, PhD

Blood (2008) 112 (11): 1017.

https://doi.org/10.1182/blood.V112.11.1017.1017

Published: 2008

Journal Articles

U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.

Melissa S. Creary, MPH, John M. Soucie, PhD, Connie H. Miller, PhD, W.C. Hooper, PhD, Thomas C. Abshire, MD, Doreen B. Brettler, MD, Paula L. Pockenstedt, MD, Jorge DiPaola, MD, Gita Massey, MD, Anne T. Neff, MD, Amy D. Shapiro, MD, Michael D. Tarantino, MD, Brian M. Wicklund, MD, Donna DiMichele, MD, Hemophilia Treatment Centers

Blood (2007) 110 (11): 1162.

https://doi.org/10.1182/blood.V110.11.1162.1162

Published: 2007

Journal Articles

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Tom E. Howard, MD, PhD, Kevin R. Viel, BS, Karl M. Fernstrom, BS, Seema Deshpande, PhD, Afshin Ameri, MD, M. Showkat Ali, PhD, Cynthia Channell, BS, Rathi V. Iyer, MD, Raymond G. Watts, MD, Charles Lutcher, MD, Shelley Nakaya, BS, Carol K. Kasper, MD, Arthur R. Thompson, MD, PhD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2006) 108 (11): 765.

https://doi.org/10.1182/blood.V108.11.765.765

Published: 2006

Journal Articles

Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency.

Marilyn J. Manco-Johnson, MD, Thomas C. Abshire, MD, Deborah Brown, MD, George R. Buchanan, MD, Alan R. Cohen, MD, Donna DiMichele, MD, W. Keith Hoots, MD, Cindy A. Leissinger, MD, Kevin McRedmond, MD, Diane J. Nugent, MD, Amy D. Shapiro, MD, Gregory A. Thomas, MD, Leonard A. Valentino, MD, Brenda Riske, MBA, MPA

Blood (2005) 106 (11): 3.

https://doi.org/10.1182/blood.V106.11.3.3

Published: 2005

Journal Articles

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

Tom E. Howard, MD, PhD, Deepa K. Machiah, BS, Kevin R. Viel, PhD, Cynthia Channel, BS, Afshin Ameri, MD, Rathi V. Iyer, MD, Ray G. Watts, MD, Charles Lutcher, MD, Joanna Davis, MD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2005) 106 (11): 3207.

https://doi.org/10.1182/blood.V106.11.3207.3207

Published: 2005

NARROW

Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States

Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program

Contribution of Select ISTH-BAT Subscores to the Total Score in Type 1 VWD

Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a

Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial

Impact of Age and Gender on Bleeding Score in Type 1 VWD Using the ISTH-BAT

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

The Kids-DOTT Trial: Novel Aspects of the ‘Parallel Cohort RCT‘ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.

Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor

U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Initial Results of a Randomized, Prospective Trial of Prophylaxis To Prevent Joint Disease in Young Children with Factor VIII (FVIII) Deficiency.

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only